Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Neoplasms 38Melanoma 36Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 10Pancreatic Neoplasms 5Neoplasm Metastasis 4Glioma 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Leukemia, Myeloid, Acute 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Ganglioneuroma 2Ganglioglioma 2Colonic Neoplasms 2Brain Neoplasms 2Astrocytoma 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Uveal Melanoma 1

Interventions

pembrolizumab 44Paclitaxel 37Carboplatin 30Doxorubicin 11Cisplatin 11Bevacizumab 11lenvatinib 9Nivolumab 9Docetaxel 9Fulvestrant 8Gemcitabine 7Oxaliplatin 6Fluorouracil 6Pemetrexed 5Letrozole 5Ipilimumab 5Cetuximab 5spartalizumab 4selinexor 4dostarlimab 4Trastuzumab 4Irinotecan 4trastuzumab deruxtecan 3tisotumab vedotin 3serabelisib 3sacituzumab govitecan 3ribociclib 3olaparib 3epacadostat 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Endometrial Neoplasms × trametinib × Clear all
NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

GlaxoSmithKline

Phase 1 Completed
240 enrolled
BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡